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Abstract:  
Background: We hypothesize that blood flow in the intestinal arteries is reduced in 
patients with stable HF and relates to gastrointestinal symptoms (GIS) and cardiac 
cachexia.  
 
Objectives: To measure arterial intestinal blood flow (BF) and its role for 
juxtamucosal bacterial growth, GIS and cachexia in heart failure (HF). 
Methods: We investigated 65 patients and 25 controls. Twelve patients were 
cachectic. Intestinal BF and bowel wall thickness (BWT) were measured using 
ultrasound. GIS were documented. Bacteria in stool and juxtamucosal bacteria on 
biopsies taken during sigmoidoscopy were studied in a subgroup by fluorescence in 
situ hybridization. Serum lipopolysaccharide-(LPS)-antibodies were measured. 
Results: Patients showed a 31-45% reduced mean systolic BF in the superior and 
inferior mesenteric arteries (SMA and IMA) and celiac trunk (CT) compared to 
controls (all p<0.004). Cachectic patients had lowest BF (p=0.0007). Lower BF in 
SMA and CT correlated with HF severity (all p<0.04). Patients had more feelings of 
repletion, flatulences, intestinal murmurs and burping (all p<0.04). Burping and 
nauseas/vomiting were most severe in cachexia (p<0.05).  
Patients with lower CT BF had more abdominal discomfort and immunoglobulin A-
anti-LPS (r=0.76, p<0.02). Anti-LPS-response correlated with increased growth of 
juxtamucosal and not stool bacteria. Patients with intestinal murmurs had greater 
BWT of sigmoid/descending colon suggestive for edema contributing to GIS 
(p<0.05).  
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In multivariable regression, lower BF in SMA, CT (p<0.04) and IMA (p=0.056) 
correlated with the presence of cardiac cachexia. 
Conclusions: Intestinal BF is reduced in HF. This may contribute to juxtamucosal 
bacterial growth and GIS in advanced HF complicated by cachexia.  
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Abbreviations 
 
FISH   Fluorescence In Situ Hybridisation 
HF   Heart Failure 
LPS   Lipopolysaccharide 
NYHA   New York Heart Association Classification  
peak VO2  peak oxygen consumption 
SD   Standard Deviation 
IQR   Interquartile Range 
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Introduction 
Chronic HF is a multisystem disease and along with increased sympathetic tone and 
chronic low-grade systemic inflammation there is an anabolic/catabolic inbalance with 
cardiac cachexia as a terminal stage of the disease. The occurrence of this 
unintentional weight loss is a serious complication and predicts poor survival (1). The 
prevalence of cachexia in chronic HF ranges from 16–42% (2). 
The role of the gut in the pathophysiology of chronic HF has only recently started to 
be investigated in detail. There is increasing evidence for the gut playing an 
important pathophysiological role for malnutrition and cachexia in chronic HF. 
Significant morphological and functional alterations of the intestine in chronic HF 
have been previously shown (3). Patients display a thickened bowel wall, suggestive 
for bowel wall edema, an intestinal barrier dysfunction and a diminished transcellular 
transport activity (4). There are increased numbers of bacteria in the mucus layer 
adjacent to the apical surface of the colonic mucosa and an increased permeability of 
both small and large intestine have been demonstrated. A restricted arterial blood 
flow to the intestine is a major candidate explaining these functional alterations and 
may create an abnormal environment in the juxtamucosal mucus layer that 
encourages the increased growth of bacteria. 
However, arterial blood flow to the intestine and gastrointestinal symptoms in 
cachectic and non-cachectic patients with HF have not been analyzed yet. 
We here hypothesize that (1) arterial blood flow in the main intestinal arteries is 
reduced in patients with stable compensated HF and (2) relates to possible 
gastrointestinal symptoms and to the (3) prevalence of cardiac cachexia.  
 
Methods 
Patients.  
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We prospectively studied intestinal blood flow in 65 patients with chronic HF and 25 
control subjects (for demographic and clinical details see Table 1). The diagnosis of 
chronic HF was based on symptoms arising during exercise, clinical signs, and 
documented left ventricular impairment (left ventricular ejection fraction [LVEF] ≤ 
40%) according to guidelines (5). Patients were classified as cachectic independently 
of their absolute BMI if they had experienced a non edematous, non intentional 
weight loss of ≥ 5% within the previous 6-12 months (6). All patients were clinically 
stable (NYHA 2.5 ± 0.1) and received unchanged medication for at least four weeks 
prior to assessments. Patients were allowed to take aspirin 100 mg once daily, but 
not other non-steroidal anti-inflammatory drugs, steroid hormones, or antibiotics 
within at least 4 weeks prior to being studied. In HF patients, medication consisted of 
angiotensin converting enzyme (ACE) inhibitors (71%), angiotensin receptor 
antagonists (32 %), beta-blockers (88 %), aldosterone receptor antagonists (52 %), 
other diuretics (72 %), glycosides (20 %) and statins (80 %) in varying combinations. 
None of the control subjects were taking any cardiovascular medication except for 
calcium channel blocker in one subject and ACE inhibitors in 2 subjects for mild 
arterial hypertension without evidence of left ventricular dysfunction. Subjects with 
clinical signs of infection, rheumatoid arthritis, renal failure, intestinal diseases, 
severe chronic obstructive pulmonary disease, significant valvular heart disease, 
cancer or history of autoimmune disorders were excluded. None of the subjects had 
any known immune system disorders and no subject received immune modulation 
therapy. The local ethics committee approved the study and all subjects gave written 
informed consent. 
 
Clinical assessments.  
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Echocardiography was performed following standard procedures. LVEF was 
measured using biplane Simpson's technique. All subjects underwent a symptom-
limited treadmill exercise testing (instantaneous breath by breath method) using the 
modified Naughton protocol (Innocor™ system; Innovision, Odense, Denmark and 
treadmill HP cosmos®; HP Cosmos sports & medical GmbH, Nussdorf-Traunstein, 
Germany). The following variables were measured: peak oxygen consumption (peak 
VO2), total exercise time, ventilatory response to exercise (VE/VCO2-slope), 
anaerobic threshold, peak heart rate (beats per minute), and peak systolic and 
diastolic blood pressures.  
 
Blood flow velocities in the celiac trunk (CT), superior mesenteric artery (SMA) and 
the inferior mesenteric artery (IMA) were measured by high resolution duplex 
ultrasonography (8-5-MHz vector-array transducer HDI 5000, Philips, Belgium) by a 
single observer (JB). Blood flow measurements were performed three times in each 
patient and the mean of three measurements used for statistical analysis. In brief, the 
investigator measured the diameter of the artery during systole from magnified B-
mode longitudinal images of the artery. Blood flow (ml/min) measurements were 
calculated using the formula: π × r 2 × TAMV × 60, where r is the radius of the artery 
and TAMV is the time-averaged mean velocity as previously described (7). The angle 
between the doppler and the mesenteric artery was <60°. Systolic blood flow in the 
SMA was assessable in 63 patients and 23 controls. Systolic blood flow in the IMA 
was assessable in 56 patients and 23 controls and flow in CT was measured in 53 
patients and 20 controls. 
Transcutaneous abdominal sonography (12-MHz linear-array transducer, HDI 5000, 
Philips, Belgium) was used to measure bowel wall thickness in the middle segment of 
the sigmoid (in subjects 1 to 65), descending, transverse and ascending colon 
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(subject 7 to 65). Measurement of the terminal ileum (subject 7 to 65) was performed 
5 cm proximal to ileocecal valve. Due to obesity, the sigmoid colon was not assessed 
in three subjects; transverse colon was not assessed in three subjects, the ascending 
colon in one subject and the terminal ileum in one subject. Patients were scanned 
under identical conditions after overnight fasting.  
Measurement of bowel wall thickness was carried out in true cross and longitudinal 
sections of the relaxed bowel by assessment of the anterior bowel wall. Overall 
thickness of the bowel wall was measured from the first mucosal interface echo to the 
first serosal echo. Each measurement was repeated three times at different positions 
of the intestinal wall and the mean was calculated.  
All sonographic recordings were performed in a standardized way, and readings were 
analysed by the same experienced physician (JB), who was blinded as to the 
subjects' study group. The intraobserver coefficient of variation for intestinal 
ultrasound measurements of bowel wall thickness repeated on consecutive days is 
5%. Accuracy of measurement is <0.2 mm for all segments. 
Venous occlusion plethysmography was performed to assess peripheral blood flow 
and vascular capacity using a plethysmograph (EC 6, Hokanson Inc., Bellevue, USA) 
system in 55 patients and 17 control subjects, as previously described (8). The 
subjects rested in a supine position for at least 15 minutes, and forearm blood flow 
was determined using a mercury-in-silastic strain gauge (Hokanson Inc., Bellevue, 
USA). A cuff around the right upper arm was connected to a rapid inflation pump with 
an air source and solenoid valves, used to inflate and deflate the occlusion cuff 
rapidly to the required pressure of 40 mmHg. To measure the peak forearm blood 
flow, the cuff was inflated to suprasystolic pressure (30 mm Hg above systolic blood 
pressure) for 3 minutes. Blood flow was measured after release of the cuff in ten 
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second intervals for at least two minutes. The highest flow results were considered to 
represent peak forearm blood flow. 
Results for plethysmography are given in milliliters per 100 mL tissue per minute 
(mL/100 mL/min). All the above assessments were performed in a dedicated quiet 
room between 9 a.m. and 10 a.m. to prevent data bias from noise and circadian 
rhythms. 
 
Gastrointestinal symptoms were assessed by Gastrointestinal Symptom Rating Scale 
(GSRS) questionnaire which was completed by 59 patients and 18 control subjects 
(9). GSRS items include abdominal pain, reflux syndrome, diarrhoea syndrome, 
indigestion syndrome and constipation syndrome (10) and have a good internal 
consistency, reliability, construct validity and responsiveness (9). 
Mucosal bacterial biofilm was assessed by Fluorescence in situ hybridization (FISH) 
in biopsies taken during sigmoidoscopy in 22 patients with chronic HF and 20 control 
subjects as previously described (3) according to the well established technique 
without sedation after a glycerol enema. 
Stool samples were available from 21 patients with chronic HF and 17 control 
subjects. Total bacteria and bacterial groups were studied by FISH and 
epifluorescence microscopy in blinded faecal samples as previously described (11). 
In 13 controls (subject 10-22) and 12 patients (subject 9-20) intestinal blood flow was 
assessed in that group. Blood immunoglobulin A-anti-Lipopolysaccharide (LPS) by 
were assessed in these patients and controls by ELISA (12, 13).  
 
In 27 patients and 18 control subjects, C-reactive protein was measured. Plasma 
concentrations of mid-regional pro-adrenomedullin and mid-regional pro-atrial 
natriuretic peptide were measured by using a chemiluminescence immunoassay on 
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the KRYPTOR System (Brahms AG, Hennigsdorf/Berlin, Germany), as previously 
described in detail (14,15). 
 
 
Statistical analysis 
Statistical analysis was performed using StatView 5.0 software (SAS Institute Inc., 
Cary, USA). Normality of distribution was assessed using the Kolmogorov-Smirnov 
test. Results are reported as mean ± SD (indicating normal distribution of data; 
statistical comparisons were made using unpaired t-test) or median (interquartile 
range) (indicating non-normal distribution of data; statistical comparisons were made 
using Mann-Whitney-U-test). Analysis of variance (ANOVA), Student's unpaired t-
test, Fisher's exact test, Pearson's simple regression, and logistic regression were 
used as appropriate. Non-normally distributed data were common-log-transformed to 
achieve a normal distribution where indicated. Parameters that were significantly 
different between non-cachectic and cachectic patients were tested using 
multivariable regression analysis. Variables of interest were adjusted for age and 
gender as indicated. A two-tailed p-value ≤0.05 was considered significant in all 
analyses.  
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Results  
There were no significant differences between control subjects and patients with 
chronic HF in terms of age and gender (Table 1). As expected, patients had a lower 
ejection fraction and peak VO2. Patients with cardiac cachexia had a lower BMI and 
were haemodynamically more severely compromised as reflected by lower peak VO2, 
lower LVEF and higher blood levels of proANP compared to patients without cachexia 
(Table 1). Patients with heart failure had higher blood concentration of white blood 
cells as compared to control subjects (Table 1). Serum concentrations of C-reactive 
protein were higher in patients compared to controls with highest levels in cachectic 
patients compared to non cachectic patients (Table 1). 
 
Intestinal blood flow 
Systolic blood flow 
Patients with chronic HF had a lower mean and peak systolic blood flow in SMA, IMA 
and CT as compared to control subjects (Table 2). The lowest systolic blood flow in 
SMA, IMA and CT was in patients with cardiac cachexia with a flow reduction by 
52%, 50% and 53% compared to control subjects. Lower mean systolic flow in both 
SMA and CT correlated with severity of heart failure in patients according to higher 
blood pro ANP (Figure 1a and b). 
We did not detect any stenoses of the mesenteric arteries or celiac trunk in either 
patients or controls. 
 
Diastolic blood flow 
Mean diastolic blood flow was lower In CT and IMA in patients compared to controls 
(Table 2). There was a trend for a lower diastolic flow in CT in patients with more 
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severe HF according to blood pro ANP (r=0.25; p=0.096). Lower maximal diastolic 
flow and in trend lower minimal diastolic flow in SMA correlated with severity of HF in 
patients according to higher blood proANP (r=0.3; p<0.03, r=0.25; p=0.077). 
 
Correlation of intestinal blood flow with forearm resting and peak post-ischemic blood 
flow and arm systolic blood pressure 
In patients with HF, both resting arterial limb blood flow (arm) and peak post-
ischemic flow are reduced, the latter indicating impaired vasodilator capacity due to 
endothelial dysfunction as compared to controls (Table 2). Higher blood mid-regional 
pro-adrenomedullin levels in patients underlined impaired endothelial function in our 
patient group (Table 1). However, there was no correlation of arm blood flow and 
intestinal blood flow reflecting adaptive mechanisms in the different zones within the 
vascular bed (all p>0.12). Arm blood pressure did not correlate with mean intestinal 
blood flow either, indicating that arm blood pressure is an insufficient marker for 
decreased intestinal flow (all p>0.4).  
 
 
Bowel wall thickness 
Patients had increased bowel wall thickness in the terminal ileum, representing the 
small bowel, ascending colon, transverse colon, descending colon, and sigmoid  
compared to control subjects (all p<0.01, Table 5). However, bowel wall thickness did 
not correlate with patients’ edema status at lower legs and lower arterial intestinal 
blood flow. 
 
Gastrointestinal symptoms 
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Patients compared to controls complained more often feelings of repletion (34/58 vs. 
4/18, p=0.014), burping (15/59 vs. 0/18, p=0.016), flatulence (43/59 vs. 8/18, p=0.03) 
and murmurs from the intestine (34/59 vs. 5/18, p=0.027). In cachectic vs. non 
cachectic patients, burping was more often and more severe (5/11 vs. 8/46, p<0.05 
and 1.8±0.4 vs. 1.3±0.3, p=0.01) and murmurs from the intestine were in trend more 
severe (p<0.08). Nauseas/vomiting, if present, were more severe, too (2.25±0.5 vs. 
1.1±0.1, p<0.02). 
 
In those patients with abdominal discomfort, we found a lower mean systolic flow in 
celiac trunk (274±36 vs. 480±38 mL/min, p=0.02). In univariate regression, both high 
NYHA class and low CT flow correlated with abdominal discomfort (all p<0.04). 
 
Patients with intestinal murmurs had a greater bowel wall thickness of the sigmoid 
and descending colon (0.23±0.017 vs. 0.18±0.01 cm, p=0.03 and 0.20±0.014 vs. 
0.16±0.01 cm, p=0.04) and a similar bowel wall thickness of terminal ileum and the 
ascending colon (all p>0.2). 
 
There was a consistent trend for increased heartburn, reflux and constipation in 
patients with chronic HF compared to controls (21/59 vs. 2/18, p=0.075, 21/59 vs. 
2/18, p=0.075 and 15/58 vs. 1/18, p=0.097). However, pain in the upper abdomen 
(14/58 vs. 2/18 individuals, p=0.3), defecation frequency (2/18 vs. 13/56, p=0.3) and 
nausea/vomiting (13/59 vs. 2/18 individuals, p=0.5) were similarly reported in patients 
vs. controls.  
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Stool bacteria 
Amount of bacteria in stool 
Concentrations and proportions of both anaerobic and aerobic bacteria in the stool 
were similar in patients compared to controls (Table 4). 
  
Relation of stool bacteria to increased specific bacteria in mucosal biofilm 
The number and composition of stool bacteria did neither reflect the higher 
concentration of mostly anaerobic bacteria in the mucosal biofilm of patients nor the 
increased proportion of strictly anaerobic Eubacterium rectale (EREC), 
bacteroides/prevotella and Fusobacterium prausnitzii in biofilm of patients (r=0.4 and 
0.3, p=0.12, p>0.17, p>0.5 and p>0.37, respectively). This points to an increase in 
bacteria restricted to the juxtamucosal zone.  
 
Correlation of intestinal blood flow with stool and juxtamucosal bacteria  
The concentration of total stool bacteria, aerobes, gram-negative aerobes, 
anaerobes, lactobacilli, enterococci, bacteroides, bifidobacteria or yeast in stool were 
not associated with lower intestinal blood flow (all p>0.1).  
In contrast, a higher proportion of the strictly anaerobic EREC in the juxtamucosal 
biofilm of the sigmoid in patients correlated with lower systolic flow in IMA supplying 
the sigmoid (p=0.047, r=0.64). 
 
Correlation of stool and juxtamucosal bacteria with serum IgA-LPS-antibodies  
In 13/22 patients with a high concentration of juxtamucosal bacteria of ≥108/mL there 
was a strong trend for an association of increased growth of juxtamucosal bacteria 
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and serum concentrations of immunoglobulin A-anti-LPS (p=0.05, r=0.55, Figure 2). 
Luminal stool bacteria did not correlate with serum IgA-LPS-antibodies. 
 
Correlation of intestinal blood flow with inflammatory markers in blood 
Lower blood flow in CT correlated with higher serum IgA-LPS-antibodies (Figure 3, 
r=0.76, p<0.02) and with higher serum C-reactive protein (r=0.61, p=0.003, Figure 4).  
Lower intestinal blood flow in SMA was associated with higher serum C-reactive 
protein in patients, too (r=0.43, p=0.02, Figure 4).  
 
 
Correlates of the presence of cachexia 
In univariate logistic regression, lower LVEF, higher blood pro ANP, higher NYHA 
class, lower intestinal flow in CT or SMA and in trend IMA were correlated with the 
presence of cachexia (Table 3). These correlations of lower LVEF, higher blood pro 
ANP, higher NYHA class, lower intestinal flow in CT or SMA with the presence of 
cachexia remained significant after adjustment for age and gender. (p<0.02, p<0.003, 
p<0.008, p<0.03 or p<0.01, respectively). 
In contrast, age, sex, arm resting blood flow and bowel wall thickness were not 
correlated with the presence of cachexia serving as the dependent variable (Table 3).  
 
In multivariate regression analysis, lower intestinal blood flow in SMA, CT (all p<0.04) 
or in trend lower intestinal blood flow in IMA (p<0.058) were independently 
associated with the presence of cardiac cachexia in distinct models each adjusted for 
NYHA, LVEF and pro ANP. The probability to be cachectic for intestinal flows each 
adjusted for NYHA, LVEF and pro ANP was 0.1 for increase in CT flow, 0.2 for 
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increase in SMA flow or 0.4 for increase in IMA flow (OR 0.1, 95% CI 0.02-0.8; OR 
0.2, 95% CI 0.04-0.8 or OR 0.4, 95% CI 0.1-1.0, respectively). 
There was a trend for higher NYHA class to be independently associated with the 
presence of cardiac cachexia in models including either CT or SMA flow (p<0.097).  
After adjustment of intestinal blood flow for age and gender, lower intestinal blood flow in CT or SMA remained correlated with 
the presence of cachexia (p<0.03 or p<0.01, respectively). 
 
Discussion 
This is the first study to evaluate blood flow in all three arteries supplying stomach, 
small and large intestine in patients with and without cardiac cachexia.  
Endothelial function of the forearm vessels revealed both a lower resting blood flow 
and a lower flow mediated flow in patients with HF compared to control subjects. 
Higher concentration of juxtamucosal anaerobic bacteria in the sigmoid colon of the 
patients correlated with the higher systemic concentration of anti-LPS IgA antibodies.  
Furthermore, there was an increase in GI symptoms in patients compared to controls. 
Patients complained more often of feelings of repletion, burping, flatulences and 
murmurs from the intestine. Symptoms were most pronounced in cachectic patients. 
Patients with abdominal discomfort had a lower mean systolic flow in celiac trunk.  
Impaired intestinal blood flow correlated with severity of HF and was in accord 
with greater thickness of the bowel wall in patients with chronic HF, suggestive of 
bowel wall edema. Patients with intestinal murmurs had greatest bowel wall thickness 
of the sigmoid and descending colon.  
 
However, patients did not have symptoms of mesenteric ischemia such as abdominal 
pain, diarrhea or obvious intestinal bleeding. The only symptoms found were minor 
and can be ascribed to changes in intestinal motor function. 
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One explanation for the increased number of bacteria in the mucosal biofilm is that 
entirely new phylotypes of bacteria are present in patients with HF. Some differences 
were found, e.g. a greater proportion of patients with chronic HF had 
Bacteroides/Prevotella, Eubacterium rectale group (EREC), Fusobacterium 
Prausnitzii (3), all representing a standing intestinal flora. Overall the range of 
bacteria within biofilm was broadly similar in patients and controls. It is therefore 
likely, that the environment in the mucosal biofilm is altered in HF patients in such a 
way that the growth of bacteria is encouraged. In particular, the higher occurrence 
rate of the strictly anaerobic Eubacterium rectale group and the strictly anaerobic 
Fusobacterium prausnitzii in intestinal biofilm indicates better conditions for these 
specific anaerobes directly at the surface of the mucus membrane in chronic HF. A 
major candidate for the cause of the environmental change in the mucosal biofilm is 
reduced mesenteric blood flow and endothelial dysfunction, as we report here. The 
correlation of lower systolic flow in IMA supplying sigmoid with the higher proportion 
of juxtamucosal strictly anaerobic EREC found in patients indicates this. Reduced 
intestinal blood flow results in limited oxygen supply to the mucosa which may cause 
this selective enrichment of obligate anaerobic gut flora in HF patients.  
Consequences of reduced blood flow do not seem to be restricted to the mucosal 
biofilm as the increased GI symptoms we describe here suggest a motor dysfunction 
of the intestine. As of now, the precise pathophysiological basis of the symptoms of 
burping, flatulence, sensation of repletion and borborygmi is not yet known a 
disturbance of motor pattern is one possible explanation. Strictly anaerobic EREC – a 
bacterial species we found to be higher in proportion at the surface of mucus 
membrane in CHF group – is known to produce high amounts of hydrogen gas, and 
therefore may contribute to the increase in intestinal symptoms such as flatulence and 
 18 
intestinal murmurs in CHF. The fact that higher proportion of juxtamucosal EREC in 
CHF correlated with lower systolic flow in IMA supplying the sigmoid suggests that 
reduced intestinal blood flow in heart failure may contribute to a consecutive increase 
in juxtamucosal bacteria thereby promoting intestinal symptoms. 
It can not completely ruled out that influences of long-term medication or a diet rich in 
carbohydrates and fibers contribute to these symptoms in patients with HF though we 
have no evidence that HF patients have a diet higher in fibre than controls.  
However, the fact that lower CT blood flow correlated with abdominal discomfort 
suggests that the GI symptoms may furthermore be due to motor defects in the gut 
secondary to ischemia.  
 
Altered arterial intestinal blood flow has not been directly described in stable patients 
with chronic HF. Intramucosal acidosis occurs in about 50% of patients with 
circulatory failure (16,17,18) pointing indirectly to an inadequate oxygen supply and 
intestinal ischemia (19). An increase in gastric intramucosal carbon dioxide pressure 
has been documented in recompensated patients with chronic HF even at low levels 
of exercise such as 25 Watt (20). The present findings of a diminished mean and 
peak systolic resting intestinal blood flow are likely to be causal for a decreased 
oxygen supply and this latent intestinal ischemia thereby challenging mucosal barrier 
integrity.  
 
The intestine investigated in this study is a highly sensitive region due to the fact that 
the bowel wall establishes the barrier to a huge amount of bacteria that are 
potentially immunogenic to the host when entering the circulation. As a potential 
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result of this, patients with chronic HF have been reported to display higher blood 
concentrations immunoglobulin A (IgA)-anti- E.coli J5 endotoxin compared to controls 
(3) reflecting a higher endotoxin bioactivity and mucosal interaction in patients. 
Niebauer et al. have found higher LPS concentrations in hepatic veins as compared 
to the left ventricle during acute HF suggestive of bacterial translocation from the gut 
into the systemic circulation (21). Therefore, the intestine is a very likely reason for 
triggering IgA-antibodies against LPS.  
The present study shows a correlation of lower blood flow in CT with higher systemic 
serum LPS IgA antibodies and an association of an increased growth of juxtamucosal 
bacteria with a higher serum concentration of IgA anti-LPS in patients with HF. Above 
a certain threshold the more bacteria there are in the biofilm, the higher the LPS 
antibodies. This points to an interaction between mucosal intestinal bacteria and 
patients’ immune system in stable HF that may contribute to the prognostically 
relevant systemic inflammation in heart failure.  
However, the extent of contribution to the systemic increase in proinflammatory 
mediators can not be concluded from this study.  
The increase in biofilm bacteria on the luminal side of the gut wall seems to be an 
initial local mucosal phenomenon not resulting in changes of the global composition 
of stool at least in stable patients with HF. The finding that stool bacteria did not 
correlate with total amount of bacteria in mucosal biofilm of sigmoid colon points to 
that future studies must be undertaken on samples of mucosal biofilm.  
 
Reduced arterial intestinal blood flow in patients is in accord with greater bowel wall 
thickness of both small and large intestine suggestive for bowel wall edema due to 
hemodynamic perturbations. An increased bowel wall thickness is a frequent finding 
in various conditions, such as acute ischemic colitis (22), inflammatory bowel disease 
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(23), and food hypersensitivity (24). The finding of an increased bowel wall thickness 
we previously described in 22 patients with chronic stable HF. In this current study on 
65 patients, we were able to confirm this finding of the thickened bowel wall in a 
larger cohort and to investigate its relation to the arterial perfusion in the 
corresponding intestinal vessels and furthermore - to intestinal symptoms in heart 
failure. There was no direct correlation of diminished arterial blood supply with the 
extend of swelling of the intestinal wall. This points to cofactors, such as venous 
congestion that may further influence the degree of bowel wall edema.  
Greater bowel wall thickness of the sigmoid and descending colon was associated 
with increased intestinal murmurs indicating a contribution of swelling of the intestine 
to intestinal symptoms. 
Impaired vasodilator capacity due to endothelial dysfunction may further aggravate 
this critical perfusion of the intestinal mucosa. Higher blood mid-regional pro-
adrenomedullin levels in patients further underscore the suspected endothelial 
dysfunction. Impaired vasodilator capacity is indicated in our patients by the lower 
forearm post-ischaemic flow. However, there was no correlation of this reduced 
resting arterial limb blood flow (arm) or peak post-ischemic arm flow or arm blood 
pressure with the reduced intestinal flow. This points to the need of assessment of 
intestinal flow in HF.   
Cachexia is a serious complication of advanced HF and one of the most important 
predictors of prognosis. Cachectic patients who had more severe HF in this study as 
reflected by higher blood concentration of pro-ANP, showed both more severe 
nauseas/vomiting and burping and lowest intestinal blood flow. In multivariate 
regression analysis with limited statistical power, the lower intestinal blood flow in 
SMA, CT and in trend lower intestinal blood flow in IMA were correlates of the 
presence of cardiac cachexia. This suggests a contribution of restricted arterial 
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intestinal blood flow to cardiac cachexia.  
 
 
Conclusion: Intestinal arterial blood flow is reduced in patients with chronic HF.  
This may contribute to increased growth of juxtamucosal bacteria, inflammation, 
gastrointestinal symptoms and cardiac cachexia complicating advanced heart failure.  
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